+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Immunotherapy for advanced renal cell cancer

, : Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews (): Cd001425-Cd001425

The course of advanced renal cell carcinoma is extremely variable, ranging from spontaneous remission to disease progression refractory to chemotherapy. Immunotherapy has held promise of improved outcomes based on uncontrolled studies and randomized controlled trials generally limited by small size and low power. To evaluate immunotherapy for advanced renal cell carcinoma by comparing: (1) high dose interleukin-2 to other options and (2) interferon-alfa to other options. The primary outcome of interest was overall survival at one year, with remission as the main secondary outcome of interest. A systematic search of the CENTRAL, MEDLINE, and EMBASE databases was conducted for the period 1966 through end of December 2003. Handsearches were made of the proceedings of the periodic meetings of the American Urologic Association, the American Society of Clinical Oncology, ECCO - the European Cancer Conference, and the European Society of Medical Oncology for the period 1995 to June 2004. Randomized controlled trials that selected (or stratified) patients with advanced renal cell carcinoma, utilized an immunotherapeutic agent in at least one study arm, and reported remission or survival by allocation. Fifty-three identified studies involving 6117 patients were eligible and all but one reported remission; 32 of these studies reported the one-year survival outcome. Two reviewers independently abstracted each article by following a prospectively designed protocol. Dichotomous outcomes for treatment remission (partial plus complete) and for deaths at one year were used for the main comparisons. Survival hazard ratios were also used for studies of interferon-alfa versus controls, and for two randomized studies of the value of initial nephrectomy prior to interferon-alfa in fit patients with metastases detected at the time of diagnosis. Combined data for a variety of immunotherapies gave an overall chance of partial or complete remission of only 12.9% (99 study arms), compared to 2.5% in 10 non-immunotherapy control arms, and 4.3% in two placebo arms. Twenty-eight percent of these remissions were designated as complete (data from 45 studies). Median survival averaged 13.3 months (range by arm, 6 to 27+ months). The difference in remission rate between arms was poorly correlated with the difference in median survival so that remission rate is not a good surrogate or intermediate outcome for survival for advanced renal cancer. We were unable to identify any published randomized study of high-dose interleukin-2 versus a non-immunotherapy control, or of high-dose interleukin-2 versus interferon-alfa reporting survival. It has been established that reduced dose interleukin-2 given by intravenous bolus or by subcutaneous injection provides equivalent survival to high dose interleukin-2 with less toxicity. Results from four studies (644 patients) indicate that interferon-alfa is superior to controls (OR for death at one year = 0.56, 95% confidence interval 0.40 to 0.77). Using the method of Parmar 1998, the pooled overall hazard ratio for death was 0.74 (95% confidence interval 0.63 to 0.88). The weighted average median improvement in survival was 3.8 months. T he optimal dose and duration of interferon-alfa remains to be elucidated. The addition of a variety of enhancers, including lower dose intravenous or subcutaneous interleukin-2, has failed to improve survival compared to interferon-alfa alone. Two recent randomized studies have examined the role of initial nephrectomy prior to interferon-alfa therapy in highly selected fit patients with metastases at diagnosis and minimal symptoms: despite minimal improvement in the chance of remission, both studies of up-front nephrectomy improved median survival by 4.8 months over interferon-alfa alone. Recent studies have been examining anti-angiogenesis agents. A landmark study of bevacizumab, an anti-vascular endothelial growth factor antibody, was associated with significant prolongation of the time to progression of disease when given at high dose compared to low-dose or placebo therapy though frequency of remissions or survival were not improved. interferon-alfa provides a modest survival benefit compared to other commonly used treatments and should be considered for the control arm of future studies of systemic agents. In fit patients with metastases at diagnosis and minimal symptoms, nephrectomy followed by interferon-alfa gives the best survival strategy for fully validated therapies. The need for more effective specific therapy for this condition is apparent.


PMID: 15674877

DOI: 10.1002/14651858.CD001425.pub2

Other references

Seino, A.K.zuma, T.T.n, A.; Tanaka,, Y.M.ta, K.S.iotsuki, T., 2007: Analysis of two acetylcholinesterase genes in Bombyx mori. Two acetylcholinesterases (AChE, EC cDNAs were identified and cloned from silkworm, Bombyx mori. One of those, BmAChE-o cDNA, is comprised of 3197 nucleotides which encode 638 amino acids, having an amino acid sequence homology of 72% wit...

Richardson R., 1999: Fishing for big ones in the depths of the Curnamona. Bulletin - Australian Institute of Geoscientists 28: 97

Siddiqui, A.M.; Cirmi, G.; Brida, D.; Kärtner, F.X.; Cerullo, G., 2009: Generation of <7 fs pulses at 800 nm from a blue-pumped optical parametric amplifier at degeneracy. We generate ultrabroadband pulses at 800 nm from an optical parametric amplifier (OPA) pumped by the second harmonic of a Ti:sapphire system and working at degeneracy. The OPA is seeded by a white-light continuum generated from a near-IR OPA pumpe...

Levitan, R.D.; Jansen, P.; Wendland, B.; Tiemeier, H.; Jaddoe, V.W.; Silveira, P.P.; Kennedy, J.L.; Atkinson, L.; Fleming, A.; Sokolowski, M.; Gaudreau, H.; Steiner, M.; Dubé, L.; Hamilton, J.; Moss, E.; Wazana, A.; Meaney, M., 2016: A DRD4 gene by maternal sensitivity interaction predicts risk for overweight or obesity in two independent cohorts of preschool children. Recent evidence suggests that early exposure to low maternal sensitivity is a risk factor for obesity in children and adolescents. A separate line of study shows that the seven-repeat (7R) allele of the dopamine-4 receptor gene (DRD4) increases su...

Doherty, C.; Fleming, R., 1976: Restoration of the alimentary tract after total gastrectomy using autosuture staplers. American Journal of Surgery 131(5): 629-632

Oysu, C.; Aslan, I.; Ulubil, A.; Baserer, N., 2002: Incidence of cochlear involvement in hyperbilirubinemic deafness. Neonatal hyperbilirubinemia remains an important cause of childhood deafness, especially in developing countries. After neonatal hyperbilirubinemia, the auditory neural pathways, cochlea, or both may be affected. In this study, we aimed to determi...

Doroshkov, A.V.; Afonnikov, D.A.; Pshenichnikova, T.A., 2015: Genetic analysis of leaf pubescence in isogenic lines of conmmon wheat Novosibirsk 67. In this study, genetic and monosomic analyses of the leaf pubescence of ANK 7A, ANK 7B, and ANK 7C wheat isogenic lines were carried out based on the Novosibirsk 67 wheat variety. According to visual analysis, the variety-recipient has a soft, uni...

Ruben P.C.; Starkus J.G., 1991: Parallel and sequential processes in slow inactivation of sodium channels. Biophysical Journal 59(2 PART 2): 71A

Grotta, J., 2001: Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole. A neuroprotective drug may be safe and effective if given very early and in combination with recombinant tissue-type plasminogen activator (rt-PA) to acute stroke patients. No clinical trial has yet tested this hypothesis. To assess the feasibilit...

Lee, I-Seon.; Choi, W.Ho.; Kim, J.Young.; Jeong, J-Yong.; Kim, M-Jung.; Nam, J-Hyun.; Kim, J-Hyeok.; Seo, S-Beom.; Pak, J.Ho., 2008: Transcriptional regulation of the murine 1-cys peroxiredoxin gene by the B cell-specific activator protein, Pax5. Pax5, a member of the paired box gene family of transcription factors, is a B cell-specific activator protein (13 SAP) that plays important roles in controlling the expression of lineage- and differentiation-stage specific genes during B lymphopo...